CA1121243A - Blood glucose control apparatus - Google Patents

Blood glucose control apparatus

Info

Publication number
CA1121243A
CA1121243A CA000315727A CA315727A CA1121243A CA 1121243 A CA1121243 A CA 1121243A CA 000315727 A CA000315727 A CA 000315727A CA 315727 A CA315727 A CA 315727A CA 1121243 A CA1121243 A CA 1121243A
Authority
CA
Canada
Prior art keywords
insulin
blood stream
glucose
subject
output signals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000315727A
Other languages
French (fr)
Inventor
Anton H. Clemens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc
Application granted granted Critical
Publication of CA1121243A publication Critical patent/CA1121243A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00Surgery
    • Y10S128/13Infusion monitoring

Abstract

Docket No. 11771 BLOOD GLUCOSE CONTROL APPARATUS Abstract of the Disclosure Apparatus is described for controlling blood glucose concentration in a subject by selected infusion of insulin into the blood stream of such subject, depending upon the general blood glucose concentration. This apparatus com-prises in combination sensor means for determining the blood glucose concentration and for providing computer input signals based on such measurement, computer means for receiving such input signals and for providing output signals based upon such input signals, and pump means responsive to such computer output signals to supply insulin to such subject at a rate determined by such output signals. The computer means is programmed to derive the output signals in accordance with specific equations employing certain inde-pendently selected values relating to basal blood glucose concentrations and basal insulin infusion rates at such basal blood glucose concentrations.

Description

Fie~d_o~ the I-~v_ntion The present invention relates to glucose monitoring systems in general, and more particularly to apparatus for controlling blood glucose concentrations in a sub~ect by selected infusion of insulin.
' ~ ~
Baokqround o~the Invention ~, Insulin is a hormone produced in the pancreas which is essential for the proper metabolism of glucose in the blood.
The failure to produce insulin in appropriate quantities results in the onset of diabetes mellitusO
Since the early l900's diabetic conditions have been treated by periodic injections of insuIin, coupled with diet and exercise control. It was initiaIly felt that such treatment could be used to completely control a diabetic condition. It is difficult, however, to avoid over or under compensation since insulin injection generaIIy cannot be timed to coincide with carbohydrate intake. Situations thus exist in which the amount of insulin present lS either in `~
excess of or less than that required to handle the specific blood glucose level at any given time. Such situatlons are especially severe when an individual with a diabetic condition is under stress conditions, such as surgery or during :
.~ , .
childbirth.
It is generally recognized that individuals do not ~ `~
~5 respond uniformly to insulin treatments and that some patients ~
are better managed by short acting (regular or Semilente) ~` -insulin which requires several injections per day, whereas -~
-2~
. . .
' '~.

.2'~ Z~3 other patients are better managed with intermediate (globln, NPH or Lente) or longer ac~ing (protamine zinc or Ultralente) insulin which require less frequent injections. Nelther the short nor the longer acting varieties of insulin is capable of regulating a patient's blood glucose concentratlon accurately on a minute-to-minute basis because of varying demands created by food and exercise. Only by following a life of balanced diet and exercise can a patient prevent sudden and.excessive changes in the requirements for insulin.
Such a regimen will maintain the patient's blood glucose concentration below an acceptable upper level, thereby limiting the possibility of hyperglycemia~ and above a safe lower limitJ thereby.limiting the possibility of hypoglycemia, ,,- ,:
Unfortunately, a dangerously low.blood g.lucose concentration can also result from the use of larger infusions of insulin ~, ;,' :
~ , to counteract a rising concentration of blood glucoseO Tkis , ' is because there is an overshoot when the concentration of ~ :.
blood glucose ceases.to.increase,or actually:decreases and ' .-, the.presence of the insulin causes.a.rapid decline in blood .' .... :
glucose concent~ation to a.concentration below the safe ; ,~
limit. The resulting hypoglycemia can be fatal in some ,; `,'-~
cases.
,., ,:
Various systems and apparatus have been proposed to '`
analyze the,blood.glucose concentration and to infuse `' ., .
insulin.or glucose based.upon.such.analysis ln an effort to control the.blood glucose level wlthin desired rangesO One .
approach, referred to.as the.limit.approach7 continuously ,~.
monitors a patient's blood glucose concentration and regu- ,.''~
. lates this concentration by.administering insulin when the ~ '., concentration reaches an.upper limit and administering ','':`"., , ..... .
":-
-3~

dextrose when the blood glucose concentration reaches a lower limit~ The limit approach, however, has several difficulties because it is possible to overshoot both the upper and lower limits The system is not capable of controlling sudden changes.in blood glucose concentration~
Another approach is to use proportional regulation by solely matching the infusion rate of insulin to the blood glucose concentration according to a linear relationship.
Here again, hypoglycemia can result if there is a large .
requirement for insulin followed by a na~ural reduction in the blood glucose concentration.
. Still another approach is.described.in Diabetes 23(5), `:"~ ;
389-40`4 (1974) in which apparatus is described having a computer which operates an inusion pump to infuse insulin : .
or glucose based upon analytical blood glucose value~s~ The computer derives its output signal for pump operation from algorithms based on hyperbolic tangential functions... While ~:
this prior art computer control has advantages, it also has the distinct disadvantage.that.the responses obtained do not `.
always satisactorily.provide adequate controlO In.addi~
tion, the apparatus.provides only limited flexibility in the selection of specific operating sonditions for particular individuals whose blood glucose concentrations are.being .~
controlled by the.apparatus. .;
. .The.development o a rapid.glucose.~analyzer with a . ~.
total.response.time.of less than.two minutes has signi~
cantly affected the systems and apparatus being usedn It is no longer necessary to calculate and.use a predicted glucose value based on.an averaging of previous glucose values, ;.
~ whether the average is an arithmetic mean or weighted ~ :

f~'~3 ~;

average, in order to compensate for a long analyzer lag.
time because the response time of a rapid analyzer approxi-mates the physiological response of a healthy subject. Th1s fact has permitted improved apparatus for monitorlng and controlling.blood glucose le~els.to be developed~

, ...Su~ma~_ Q~ the Invent~on An object of the present in~ention is to provide :~
apparatus.for accurately.monitoring the blood.glucose level , in a subject.
Another object of the present in~ention is to provide apparatus.for.~ery accurately controlling.the amount of .-insulin supplied to a subiect based,upon an.algori~hm controlled computer signal.
Still another object.o.the present invention is to provide insulin infusion apparatus which has a high degree of flexibility in the selection.of specific operating conditions for the particular subject whose blood glucose concentrations are being controlled by the apparatus" ;~ ~
In accordance with.the.present.inventionJ apparatus is `,.. '.
provided or.controlling the.concentration o glucose in the `~
blood stream.of a subiect by controlled infusion of insulin ' ,.
to the subject dependent upon the concentration of glucose in the sub~ect's.blood.stream~.such apparatus comprising in .
combination,means or determining serial ~alues of blood ` ~-glucose,concen~ration in the.blood stream.of.a subject and for providing computer input.slgnals.corresponding to sald' ',.~,'.
serial values; computer means connected.to said first mentioned.means and operable to.p~ovide output signals in ~.Z ~2 ~ 3 response to the said input.signals; and infusion means connected.to said computer.means and to a source of insulin and responsive to said output signals for introducing . insulin from said.source to caid blood s~ream at.a rate determined by said ~utput.signals; said computer means being programmed to.pro~ide J in response to.said input : -signals, output signalc causin~.said infusion means to ~ ;
introduce insulin.to said.blood stream at a rate derived in accordance with.. the following-e~uation: :.

IR = ~ + l~n + K~
` .

wherein: IR = insulin infusion.rate, RI = required basal infusion rate at BI, . -.
G = the last.~lucose.value, BI = the desired basal or steady state glucose concentration, ;
QI = is a preselected.value dependent upon the subject, .
:., K = is a preselected value dependent upon the ., subject.and.whether or not the blood glucose `: i ... .. ..
. . concentration.~ the subject.is rising (KR) . ~-or falling ~KF), ~"
t = time, and n = a number ranging from 1 to 3 ~:.
'~
,' ':

,, . ,.. ~.. ~
-6- ~

~ ~.2~

Brief DescYi~tio~ o;~_the Dr ?~in~s Other and ~urther objects, advantages and,eatures of ~;:
the invention will be apparent to those skllled.ln the art '~
from the following detailed description thereof, taken ln conjunction with the accompanyi~g drawings, in which:
Fig.. 1 is a schematic view of apparatus according to the invention coupled to.a,diabetic subject;
Fig. 2 shows a family of curves representing operation ~
of the apparatus of.the present invention i~ a first ~. ,~,.
control mode contrasted to a cur~e illustrating insulin - ;~
infusion rate vs. blood glucose concentration.outside the ';
scope of claimed operation; ';
Figs. 3-5 show families of curves representing ~ ,.'.
operation of the apparatus o the'present inventlon in the . ;',' first control mode~ said curves illustrating~insulin infusion `~.
rate vs. blood glucose concentratlon for several basal or ,~
steady state glucose concentrations at.ualues of n equal to 1, 2 and 3, respectively; ''~
Figs. 6-8 show families of curves represen~ing operation ~ ~ ''...
of the apparatus.of the present invention.in the first .
control mode, said curves illustrating insulin in~usion ~`'';, rate vs. blood glucose concentration for~several required~
basal infusion rates at values of n.equal to 1, 2 and 3, ",,'.
respectively.
Figs. 9-11 show families of curves representlng ,:,.~'~
operation of the apparatus of the present~invention in the .. ~' first control mode, said curves lllustrating insulin lnfuslon rate vs. blood glucose:concentration for several values of "~'~
QI at values of n equal to 1, 2, and 3, respectively; and ',~ .

- 7 ~
~,. .

.. , . , ,: ~ , ~ : :;, ... . . .

Figs. 12-14 show families of curves representing operation of the apparatus of the present invention in the second control mode, said.curves illustrating insulin infusion rate V5r blood,glucose concentratLo~ for.several values of m at different.. values of KR and KF, as deflned herein~

. Descr*~t?.on_~ the Preferred Embodiment,s The apparatus forming the subject matter of the present invention for controlling the.concentration of glucose in '~ ' the blood stream of.a subject.by.controlled supply of '~`.
insulin to the.subject dependent.upon the rate of Fhange of glucose concentratio~ in.said.blood.stream~is.characterized ',-: ., by means for determining serial ualues of blood glucose .. ' ,':
concentration in the.blood.stream of a subject and for ; .
15 . . pro~iding computer.input.signals~.corresponding to said ,.
serial.values; computer.means.coupled to.said first mentioned ~'.
means and operable to pro~ide.output si~Dals in response to ~ ~
said input signals; and infusion means connected to said '. :`
computer.means.and to.a.source.of.insulin and responsive to . said output.signals for.introducing.insulin from said source to said.blood.stream at .a. rate.determined by said output ~"'`
signals; said.computer.means.being programmed:to.provide, in response.to.said.input signals,.output signals causing said infusion means.to.introduce.... insulin.to said.blood stream at 25 , .a rate deri~ed.in.accordance.. .with the ollowing equation:
.
I~ d R~ T__ + l)n , K~

:

~':
wherein: IR = insulin infusion rate, RI = required basal infusion ~ate at BI, G = the last.glucose.value, ~ :
B~ = the desired.basal or steady state ~lucose concent.ration, QI = is a preselec~ed.value depe~dent upon ~ -the subject, K = is a preselected.~alue dependent upon the `: :
subject and whether.or not the blood.glucose .-concentration.of the subject is.rising (KR) or falling (KF) 3 .`' t = time, and ~ .
n = a number ranging.from 1 to:3 ~;
'' ;`:
., .
As shown schematical.ly in Figo 1, blood is removed from the blood.stream of subject lO.by.suitable:means~,~such as ~ .
through a.double.lumen.catheter (not shown) r .~hich also .:, .
introduces an anticoagulant:such~.as heparin,. in line 12, which .~.
is mixed with the blood as it lea~es the.subject, thereby . ~-diluting the blood passing~throu~h.llne 13~ The antico~
agulant.is stored in.reservoir.l4 and.is pumped to the~
cstheter.throu~h lines 16 and.12~by suitable.means, such as~
peristaltic pump 18,.which also pumps diluted blood from the `~-catheter through line.l3..i~.the opposite direction. Pump 18 runs continuously to drive the.diluted blood..rom llne 13 into glucose analyzer:22.
Glucose.analyzer 22 can..take.a ~ariety of forms. For .
example, using a.colorimeter approach7 diluted blood enters analyzer 22.and is diluted.urther.with a physiol.ogical , . ~ . :-, . .
. g - .;,'' ~ ~

,.

: -:
.

~ 3 saline solution before being segmented with al~ into dls-crete bits to be dialy7ed a~ainst a ~lucose oxidase-peroxidase-chromogen reagent. The presence of blood gluco~e specifically alters the color of the reagent and the opt1ca density of the resulting color is measured by a colorlmeter which generates a corresponding output signal. The resu~t-ing signal is then fed to analog-to-dlgltal converter 26 which prepares the input signal fo~ dlgltal computer 28.
In a preferred embodiment glucose analyzer 22 is a membrane type polarographic assembly which measures the glucose level of the diluted blood and generates a corre- .
sponding signal which is supplied to analog-to-dlgltal :
converter 26 which prepares the input signal for digltal computer 28. Suitable membrane type polarographlc apparatus is described, for example, ln U.S. Patent ~o. 4,092,233 issued M~y 30,197~. In this U.S. application a membrane lS
disclosed containing glucose oxidase which converts glucose ~ `~
to hydrogen peToxide which is detected in the po1arograph1c assembly by a difference in electrlcal potentia1 Analog-to~digital converter 26 feeds the dlgltal lnput signal corresponding to the blood glucose level to computer 28, which is programmed according to an algorithm whlch Wl11 -~""` `
be discussed later. Responsive to the signals from analyzer 22, the computer determines t~e infusion rate of insulln for ~5 the subject by use of the algorithm programmed lnto the computer. Once the infusion rate requlred by the subject has been determined, digital signals are fed from computer 28 to pump interface 32 which controls the infuslon pump1ng wh1ch `~
will no~ be described. Pump 34 connected to 1nterface 32 receives insulin from reservoir 36 b~ way of line 38 and ~.Z~ 2 ~ ~

feeds the insulin into lines 39 and 400 Line 42 receives saline solutîon from pump 44, whïch draws said solution from :~
reservoir 46. Accordingly, insulin from reservoir 36 is mixed with saline solutlon as lt lS fed into 11ne 40, and the resulting solution is introduced into the blood stream of subject 10 through a suitable catheter (not shown). A
closed loop is therefore provided which includes subject 10.
It will be understood that while the use of a digital computer is preferred, converter 26 and computer 28 can be replaced by an analog computer, if desired~ Pump 34 would then be driven in analog fashion rather than in digital fashion. :.
- As will be apparent, the regulation afforded by the structure described with reference to Fig~ 1 depends on computer algorithms programmable into computer 28 ldeally, `:
the algorithms should be capable of interpreting requirements for insulin to the point where the blood glucose concentra~
tion of a subject ls maintained substantially constant at a level which is considered normal for the subject 1n questlon. -~0 An insulin dependent diabetic requlres a static lnsulln ~ ` :
release supplemented by a dynamic control function.
Algorithms have been developed which allow investi-gators to use the present system for:
- .,:
(1) Static control - a control mode of operatlon in which insulin release is dependent upon the statlc value of ~;
the blood glucose level;
(2) Dynamic control - a control mode in which lnsulln:
infusion is controlled solely by the rate of change of blood glucose levels; and .: - ., . ~ , . . . ..

~3) Static plus Dynamic Control - a control mode 1n which dynamic control and static control are combined for controlling insulin infuslon Durîng the development of the control algorithms the static control has been optimized so that an elevated glucose level can be reduced asymptotically into the normal range without overshooting into the hypoglycemic state~
Furthermore, the static control alogrithm allows control `
constants to be selected directly for the area of physio^
logical significance, such as the basal insulin infuslon rate, the glucose level at which the basal rate should occur, and the "gain" of the control function, as expressed by the expression:
RI (-~T-__ + l)n ~ ;~
Thus, in contrast to earlie~ control algorithms uslng the '`tangens hyperbolicus", the static control algorithm of the present invention does not have control constants selected "
primarily to relate to the central portion of the control curve and only secondarily to the critical control region around and slightly above the physi~ogical range. Moreover, instead of maintaining fixed relationships for the dynamlc control conditions, the present system utilizes separate control constants during dynamic control for increasing and ;;
decreasing blood glucose levelsO `
In the past, simple averaging of the most recent blood glucose concentration value (BG) readings was used to predict the next BG valueO Simple averaging, however, has not provided satisfactory results. Unsatisfactory results have also been obtained when attempts have been made to ".

`,.

predict a BG value by using a weighted scale in whlch a number of previous BG signals received by the computer are weighted with the greatest weight being applied to the last reading As indicated, the apparatus of the present in~ention lS
capable of operatlng in several modes at the choice of the :
operator. In the first or so-called static control mode 9 : `
insulin is infused into the blood stream of a subject at a - -~
rate dependent upon the static value of the blood glucose . .
concentration. In this first mode o operation the computer ~-is programmed to provide, in response to the serial input signals, output signals causing infusion of insulln at a ` .
rate derived in accordance with the equation~
IR = RI ~ T- + l~n wherein IR = the insulin infusion:rate, RI = the required basal insulin infusion rate at BI, G = the last glucose value, :
BI = the desired basal (steady state) glucose concentration, QI = a preselected value depending upon the subject, :~
and ~ ~
n = a number ranging from l to 3 ::
-.
In order to obtain an accurate value and simultaneously to avoid the "noise" due to small minute-to-minute analyzer . . .
output fluctuations, a preferred algorithm of the present :~
invention has been developed using a least squares regres-sion line~ For this preferred embodiment the slope (m) for five co~secutive glucose values Go to G4, with Go belng the most recent glucose value, becomes:
m = 0 1 3._ 4 ,, '~ '' '':" ' ' ' ;~"'' ~ 2 ~ ~

and the value of the last glucose value ~Gy), corrected to fit the regression line, becomes:
Gy = 2m ~ Go _Gl G2 G3 G4 Substituting Gy for G the preferred equation for the flrst `~
mode becomes: -.
IR = RI (GY - BI + l)n In the second or dynamic control mode of operation, insulin is infused at a rate dependent solely upon the rate of change of blood glucose levels, and the computer ls pro-grammed to provide, in response to the serial input signals, ~ -output signals causing infusion of insulin at a rate derived in accordance with the equation: --.~-IR = K
wherein IR = the insulin infusion rate, K = a preselected value dependent upon the sub~ct and whether or not the blood glucose concen-.,-.: ,. .
- tration of the subject is rising (KR) or falling ~KF), ~. .
G = the last glucose value, and t ~ time :.

. j .

This equation is modified in a preferred embodiment to ~ .
incorporate the slope of the least squares regression llne ~.
fit for the most recent blood glucose values to become~
IR = K~
'` ~; `
-14- ~ :

" ~i 3 :.
-When this equation is modified to incorporate a factor proportional to the difference between the actual and desired glucose level the equation becomes IR=Km(G - BI) except when G is less than BI, in whîch event IR equals ~ `~
zero. Using Gy instead of G the final preferred equation for the second mode becomes:
IR = Km ~Gy - BI) ~`
except when Gy is less than BI, in which event IR equals zero. For computational convenience this equation can be written as follows: . `
IR = ~ (Gy-BI) by also increasing the values of K by a factor of 10.
In the third or static plus dynamic control mode of ~
operation, insulin is infused at a rate dependent upon both - .
the first and second modes and the computer is programmed to provide, in response to the serial input signals, output signals causing infusion of insulin at a rate derived in .
accordance with the equation: ~
IR = RI (GQI Bl + l)n ~ K~
and preferably:
IR = RI (GyQ~ BI ~ l)n ~ Km (Gy - Bl) .~;
except when Gy is less than BI, in which event said rate is :~
derived in accordance with the equation: -IR = RI (Gy QIRI + l)n . . ;;
wherein: IR = insulin infusion rate, -RI ~ required basal infusion rate at BI, Gy ~ the last glucose value, corrected to flt -a least squares regression line, ~ :
BI = the desired basal (steady state) glucose concentration, `''' '~
-I5~
' ' QI = is a preselected value dependent upon the subject, K = is a preselected value dependent upon the subject and whether or not the blood glucose concentration of the subject is rislng (KR) or falling (KF), m = is the slope of the least squares regression line fit for the most recent consecutive blood glucose values, such as~the last five blood glucose vaiues, and n = a number ranging from 1 to 3 In the above equations IR and RI are expressed in milliunits of insulin per minute of infuslonO Bl and QI are expressed in milligram percent of glucose. This can also be ~-expressed as milligrams per deciliter (mg/dl~. Bl represen~s i a selected or desired basal blood glucose concentratlon which typically would be present in a normal subject under ` i resting conditionsO RI represents the require~d basal insulin infusion rate provided by the body of~a normal subject under such conditions and is typically about 10 milliunits per minute for a person having 50 kilograms of body weight~ ~ i Thus, when the apparatus of the present inventlon is used i~ `
with a 70 kilogram human subject, for example, Rl is typl-cally about 14 milliunits of insulin per minute~ Bl is .
about 80 milligram per deciliter glucoseO A nomlnal Ql is .
about 30 mg/dl of glucose with Ql values ranging from about 5 to about 30. K will have a nominal value (KR) of approxi- ~ ~
mately 30 when the blood glucose level is rislng and a `
nominal value (KF) of approximately 8 when the glucose level is falling, if the expresslon T~ (Gy - BI) is used.

~ 3 It has been determined that in order to prevent any excess infusion of insulin in hyperglycemic condltions the infusion rates for insulin should have a controlled maximum value. A maximum însulin infusion rate of about 500 m~ unlts per minute or less has been found suitablen Typical operating conditions for computer calculated insulin infusion rates (IR) vsO measured serial blood glucose concentrations tG) for the first mode of operation are shown in Figure 2 and controlled with operating conditions outside the scope of claimed operation. Rl and BI are kept constant at typical values of lO milliunits per minute and 80 mg/dl respectivelyO QI is maintained at values of 7, 30, 57 and 85 mg/dl for values of n equal to 1, 2, 3 and 4, respectively.
The calculated IR is then obtained from the appropriate curve depending on the measured blood glucose readlng (G) , and the value of n selected by the operator. Comparable curves can also be obtained for different values of n.
Typical operating conditions or computer calculated i~nsulin infusion rates (IR) vs. measured serial blood glucose concentrations (G) for the first mode of operation are shown in Figures 3-5. RI is kept constant at a typical value of 10 mu/min. QI is maintained at 7 mg/dl for n equal to l, 30 mg/dl for n equal to 2 and 57 mg/dl for n equal to 3. BI is shown for three typical values of 60 9 80 9 and 100 mg/dl. ;';
The calculated IR is then obtained rom the appropriate curve depending on the measured blood glucose reading (G) and the appropriate BI selected by the operator~ Comparable curves can also be obtained for diferent values of BI.
Typical operating conditions for computer calculated insulin infusion rates (IR) vs. measured serlal blood ;`

z~

glucose concentrations (G) for the first mode of operatlon are shown in Figures 6-8. BI is kept cons~ant at 80 mg/dl.
QI is maintained at 7 mg/dl for n equal to 1, 30 mg/dl for n equal to 2 and 57 mgldl for n equal to 3. RI ïs shown for three values. The calculated IR is ~hen obtained from the appropriate curve depending on the measured blood glucose reading (G) and the appropriate RI selected by the operator.
Comparable curves can also be obtained for different values of RI.
Typical operating conditîons for computer calculated insulin infusion rates (IR) vs. measured serial blood glucose -~
concentrations ~G) for the first mode of operation are also shown in Figure 9-11. BI and RI are kept constant at ` `
typical values of 80 mg/dl and 10 milliunits per minute, ~ ;
respectively. QI is shown for values of 5, 7 and 9 mg/dl for n equal to 1, 20, 30 and 40 mg/dl for n equal to 2 and 47, 57 and 67 mg/dl for n equal to 3. The calculated IR ~
is then obtained from the appropriate curve depending on the ` ~;
m~asured blood glucose reading (G) and the appToprlate QI
selected by the operatorO Comparable curves can also be ` ``;
obtained for different values of QI.
Typical operating conditions for computer calculated insulin infusion rates ~IR) vsO measured serial blood glucose ~
concentrations ~G) for the second mode of operation plotted ; ``
for various values of m are shown in Figures 12-14. BI lS
kept constant at 80 mg/dl. The calculated IR is obtained from the appropriate curve depending on the measured blood - `
glucose reading (G) for different values of KR and KF. ;;~

. ;, ~z~

Using the third mode, as described herein, ~he insulin infusion rate was determined for a human subjectu Table I
illustrates calculated IR values based on the glucose levels obtained from the human subjectO The following preselected values were used:

RI = l8 mu/min, BI = 80 mg/dl, QI = 30 mg/dl, KR = 30 when the blood glucose concen-tration of the subject was rising, KF = 8 when the blood glucose concen-tration of the subject was falling.
based on the expression ~ (Gy -:BI) ." ..~.,.

,:
. ,~ .

: .'^.
'` ;~
"' , - 19 - .,,~ .
.. .;, ~, i - . .
Ta~ble I

G IR : :

102 84 `:: -101 85 : ~ . .
101 58 ~-.:
101 50 :

102 59 ~:
102 ~ 60 103 83 :
, .

lS 104 : : ~ 85 107: ~ ~ 147 : ; `~
1 0 8 ~ 1 9 1 .
- ......................... ... .... ......... ... ... ... ... ... .......... .......... ... .... ... ..... ... ... ... .. ~
1 0 7 ~ 1 8 ~ 7 109 ~ 156 2 0 I 12 ~ 19 0 1 1 4 ~ : ~ 2 5 5 , ~ i :, 114 ~ 218 1 1 3 1 4 3 ;
~ . ,.,; .

116 ~ 126 116 : 162 :., , 117 ~ 201 . , :. ~. . :
- 2 0 - . ; i , .;, : ~ .', ~ .Z~2 G (cont ' d. ) IR (cont ' d. ) 106 19 ~ `
107 29 ~:

lO0 17 ~:
100 22 :
' `-100 48 .
. ...
lO0 50 . : ~ ~
100 48 - ~ ~.
96 31 ~ "
.. ...

: . :, i .

.-. ::;-94 : 36 ~`
.~.-.

93 35 :

.
- 21 - : ~ ::
..
,: ~
:. ~` `.

~ 2~2~3 , G (cont ' d. ) IR (cont ' d . ) 92 37 :

' " , `'~:
: `:
, ~, ',' ,~
~'.' ..~,~`' :::~ .~: .
~,, ;. ~
:;.; :, ' '~','" ~, . .
:

-~
"`,-"~ , ,, ,~, "
- 2 2 - : :
4~

In the apparatus of Fi~ure 1 anv suitable sensor means can be employed to measure the blood glucose concentration of the blood samples obtained from the patient. Like-:ise an~
suitable pump can be used in the insulin infusion means. The particular details of sensor 22, compùter 2& or pumps 18, 34 and 44 do not form a part of the present invention.
Although not part of ~he present invention, it will be understood that the apparatus employed to infuse insulin can be used to also infuse glucose when glucose infuslon is necessary in order to maintain the desired blood glucose -concentration. A suitable algori~hm controlling the input of glucose is disclosed in U.S. Patent No. 4,055,175 `"
issued October 25, 1977. ~ ~
; The present apparatus can be designed to provide an ~ -alarm when physiological levels have been exceeded. FOT
example, the alarm can function to indicate hypoglycemia or hyperglycemia in a subject. Safeguards, such as means for automatically stopping infusion of insulin under.prede-termined conditionsj can likewise be incorporated~ if desired. ¦
From the foregoing, it will be seen that this invention -is well adapted to attain all of the ends and objects hereinabove set forth, together with other advantages which are obvious and which are inherent to the system. It can be seen from the above discussion that the apparatus of the present invention provides considerable flexibilit!t to the operator to select not only the specific desired mode of operation, but also to selected desired control ~talues in ¦
the computer operating equation for the selected operating ¦;
mode. The significance of the separation of the Yarious control modes 1, 2 and 3 is especially apparent in the I ~ .

-23- ~
.~ .

~ ~Jz~z~
:

research field. While it is true that ~he insulin-dependent :
diabetic requires operating mode 3, the avaïlability of a -"pure" derivative control, such as operating mode 2, helps to clarify an important question as to whether "maturi~y- -onset" diabetes is the result of a lacking "first phase"
release or a consequence of a reduced number or sensitivity of insulin receptors, or bothO
Unlike previous bi-quadratic function algorithms for .:~
"static control" mode l utilizes an exponential function wherein the exponent can va~y from l to 3. One advantage of havin~ the algorithm for "static" control as an exponential function in which the exponent varys from 1 to 3 rather than :`;
a bi-quadratic function is a reduction in the static gain .;~ :
for the elevated glucose range, an increase in gain in the range immediately above the BI level and a reduction in gain below the BI glucose level. This results in an Increase in glucose stabilizing effect of the static control algorithm about the BI glucose level, whlle concurrently reducing the ~.
; static insulin release at substantially elevated glucose :
levels, like severe hyperglycemic conditions. Moreover, the -~
.
algorithms used avoid one serious shortcoming of ear.lier algorithms, namely the sensitivity of feedback control output to a "noisy" input signal, particularly noise due to small minute-by-minute analyzer output fluctuationsO It will be understood that while preferably the letter "n" in the ,. ..
algorithms of the present invention is the integer l, 2 or :: .
3, and most preferably 1 or 2, "n" can be any decimal number ~ ~ ;
between 1 and 3.
Obviously, many other modifications and varlations of 30the invention as hereinbeore set forth may be made without ; ~-~
departing from the spiri~ and scope thereof.
~.
-Z4- ~ ~
~ ,,

Claims (13)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon both the concentration of glucose and the rate of change thereof in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentration in the blood steam of a subject and for providing computer input signals corresponding to said serial values; computer means connected to said first-mentioned means and operable to provide output signals in response to said input signals;
and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
wherein: IR = insulin infusion rate, RI = required basal infusion rate at BI, G = the last glucose value, BI = the desired basal or steady state glucose concentration, QI = is a preselected value dependent upon the subject, K = is a preselected value dependent upon the subject and whether or not the blood glucose concentration of the subject is rising (KR) or falling (KF), t = time; and n = a number ranging from 1 to 3.
2. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon both the concentration of glucose and the rate of change thereof in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentration in the blood stream of a subject and for providing computer input signals corresponding to said serial values; computer means connected to said first-mentioned means and operable to provide output signals in response to said input signals;
and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said out signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
except when Gy is less than BI, in which event said rate is derived in accordance with the equation:
wherein: IR = insulin infusion rate, RI = required basal infusion rate at BI, Gy = the last glucose value, corrected to fit a least squares regression line, BI = the desired basal or steady state glucose concentration, QI = is a preselected value dependent upon the subject, K = is a preselected value dependent upon the the subject and whether or not the blood glucose concentration of the subject is rising (KR) or falling; (KF), m = is the slope of the least squares regression line fit for the most recent consecutive blood glucose values; and n = a number ranging from 1 to 3.
3. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon both the concentration of glucose and the rate of change thereof in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentration in the blood steam of a subject and for providing computer input signals corresponding to said serial values; computer means connected to said first-mentioned means and operable to provide output signals in response to said input signals;
and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
wherein: IR = insulin infusion rate, RI = required basal infusion rate at BI, G = the last glucose value, BI = the desired basal or steady state glucose concentration, QI = is a preselected value dependent upon the subject, K = is a preselected value dependent upon the subject and whether or not the blood glucose concentration of the subject is rising (KR) or falling (KF), and t = time.
4. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon both the concentration of glucose and the rate of change thereof in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentration in the blood stream of a subject and for providing computer input signals corresponding to said serial values; computer means connected to said first-mentioned means and operable to provide output signals in response to said input signals;
and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said out signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
except when Gy is less than BI, in which event said rate is derived in accordance with the equation:
wherein: IR = insulin infusion rate, RI = required basal infusion rate at BI, Gy = the last glucose value, corrected to fit a least squares regression line, BI = the desired basal or steady state glucose concentration, QI = is a preselected value dependent upon the subject, K = is a preselected value dependent upon the the subject and whether or not the blood glucose concentration of the subject is rising (KR) or falling (KF); and m = is the slope of the least squares regression line fit for the most recent consecutive blood glucose values.
5. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the concentration of glucose in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentrations in the blood stream of a subject and for providing computer input signals corresponding to said serial values, computer means connected to said first mentioned means and operable to provide output signals in response to said input signals; and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said course to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
wherein: IR = the insulin infusion rate, RI = the desired basal insulin infusion rate at BI, G = the last glucose value, BI = the desired basal or steady state glucose concentration, and QI = a preselected value depending upon the subject.
6. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the concentration of glucose in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentrations in the blood stream of a subject and for providing computer input signals corresponding to said serial values, computer means connected to said first mentioned means and operable to provide output signals in response to said input signals; and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce Insulin to said blood stream at a rate derived in accordance with the equation:
wherein:
wherein: IR = the insulin infusion rate, RI = the required basal insulin infusion rate at BI, G = the last glucose value, BI = the desired basal or steady state glucose concentration, and QI = a preselected value depending upon the subject.
7. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the concentration of glucose in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentrations in the blood stream of a subject and for providing computer input signals corresponding to said serial values, computer means connected to said first mentioned means and operable to provide output signals in response to said input signals; and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
wherein: IR = the insulin infusion rate, RI = the required basal insulin infusion rate at BI, G = the last glucose value, BI = the desired basal or steady state glucose concentration, and QI = a preselected value depending upon the subject
8. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the concentration of glucose in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentration in the blood stream of a subject and for providing computer input signals corresponding to said serial values; computer means connected to said first mentioned means and operable to provide output signals in response to said input signals; and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
wherein: IR = the insulin infusion rate, RI = the required basal insulin infusion rate at BI, Gy = the last glucose value, corrected to fit a least squares regression line, BI = the desired basal or steady state glucose concentration, and QI = a preselected value depending upon the subject.
9. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the concentration of glucose in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentration in the blood stream of a subject and for providing computer input signals corresponding to said serial values; computer means connected to said first mentioned means and operable to provide output signals in response to said input signals; and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
wherein:
wherein: IR = the insulin infusion rate, RI = the required basal insulin infusion rate at BI, Gy = the last glucose value, corrected to fit a least squares regression line, BI = the desired basal or steady state glucose concentration, and QI = a preselected value depending upon the subject.

. -36-
10. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the concentration of glucose in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentration in the blood stream of a subject and for providing computer input signals corresponding to said serial values; computer means connected to said first mentioned means and operable to provide output signals in response to said input signals; and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
wherein: IR = a the insulin infusion rate, RI = a the required basal insulin infusion rate at BI, Gy = the last glucose value, corrected to fit a least squares regression line, BI = the desired basal or steady state glucose concentration, and QI = the preselected value depending upon the subject.
11. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the rate of change of glucose concentration in said blood stream, said apparatus comprising means for determining serial values of blood glucose concentration in the blood stream of a subject and for providing computer input signals corresponding to said serial values; computer means connected to said first-mentioned means and operable to provide output signals in response to said input signals; and infusion means con-nected to said computer means and to a source of insulin and responsive to said output signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
wherein: IR = the insulin infusion rate, K = a preselected value dependent upon the subject and whether or not the blood glucose concentration of the subject is rising (KR) or falling (KF), G = the last glucose value, and t = time.
12. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the rate of change of glucose concentration in said blood stream said apparatus comprising means for determining serial values of blood glucose concentration in the blood stream of a subject and for providing computer input signals corre-sponding to said serial values; computer means connected to said first-mentioned means and operable to provide output signals in response to said input signals; and infusion means connected to said computer means and to a source of insulin and responsive to said output signals for intro-ducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
IR = Km wherein: IR = the insulin infusion rate, K = a preselected value dependent upon the subject and whether or not the blood glucose concentration of the subject is rising (KR) or falling (KF), and m = the slope of the least squares regression line fit for the most recent consecutive blood glucose values.
13. Apparatus for controlling the concentration of glucose in the blood stream of a subject by controlled supply of insulin to such blood stream dependent upon the rate of change of glucose concentration in said blood stream said apparatus comprising means for determining serial values of blood glucose concentration in the blood stream of a subject and for providing computer input signals corre-sponding to said serial values; computer means connected to said first-mentioned means and operable to provide output signals in response to said input signals; and infusion means connected to said computer means and to a source of insulin and responsive to said out signals for introducing insulin from said source to said blood stream at a rate determined by said output signals; said computer means being programmed to provide, in response to said input signals, output signals causing said infusion means to introduce insulin to said blood stream at a rate derived in accordance with the equation:
IR = Km (Gy - BI) except when Gy is less than BI, in which event IR equals zero, wherein: IR = the insulin infusion rate, K = a preselected value dependent upon the subject and whether or not the blood glucose concentration of the subject is rising (KR) or falling (KF), m = the slope of the least squares regression line fit for the most recent consecutive blood glucose values, Gy = the last glucose value, corrected to fit a least squares regression line, and BI = the desired basal or steady state glucose concentration
CA000315727A 1977-11-25 1978-11-02 Blood glucose control apparatus Expired CA1121243A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US854,508 1977-11-25
US05/854,508 US4151845A (en) 1977-11-25 1977-11-25 Blood glucose control apparatus

Publications (1)

Publication Number Publication Date
CA1121243A true CA1121243A (en) 1982-04-06

Family

ID=25318873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000315727A Expired CA1121243A (en) 1977-11-25 1978-11-02 Blood glucose control apparatus

Country Status (9)

Country Link
US (1) US4151845A (en)
JP (1) JPS5482885A (en)
CA (1) CA1121243A (en)
DE (1) DE2849367B2 (en)
FR (1) FR2409741A1 (en)
GB (1) GB2009460B (en)
IT (1) IT1106148B (en)
NL (1) NL7811583A (en)
SE (1) SE7812146L (en)

Families Citing this family (353)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370983A (en) * 1971-01-20 1983-02-01 Lichtenstein Eric Stefan Computer-control medical care system
US4308866A (en) * 1978-11-02 1982-01-05 University Of Southern California Infusion controlling apparatus and method
US4533346A (en) * 1979-06-26 1985-08-06 Pharmacontrol Corporation System for automatic feedback-controlled administration of drugs
DE3018641C2 (en) * 1980-05-16 1986-05-28 Hans 8228 Freilassing Rodler Automatic infusion pump
IT1142930B (en) * 1981-11-04 1986-10-15 Luigi Bernardi PORTABLE APPARATUS THAT INFUSES INSULIN ON THE BASIS OF GLYCEMIC DETECTION
JPS58163335A (en) * 1982-03-23 1983-09-28 株式会社 メディランド Multi-term blood continuous monitor apparatus
JPS58198351A (en) * 1982-05-15 1983-11-18 株式会社京都第一科学 Method and apparatus for continuously measuring specific component in diluted liquid
US4464170A (en) * 1982-09-29 1984-08-07 Miles Laboratories, Inc. Blood glucose control apparatus and method
US4826810A (en) * 1983-12-16 1989-05-02 Aoki Thomas T System and method for treating animal body tissues to improve the dietary fuel processing capabilities thereof
DE3501534A1 (en) * 1984-09-22 1986-05-15 Walter Ing.(grad.) 7758 Meersburg Holzer METHOD AND DEVICE FOR DOSING INSULIN OR SIMILAR LONG-TERM MEDICINES
DE3601730A1 (en) * 1985-01-23 1986-09-11 Horst 2000 Hamburg Mau Method and device for identifying and controlling body fluid values
US4680268A (en) * 1985-09-18 1987-07-14 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
DE3545260A1 (en) * 1985-12-20 1987-06-25 Juergen Schrezenmeir DEVICE FOR THE CONTINUOUS OR DISCONTINUOUS ADMINISTRATION OF INSULIN IN HUMAN BODIES
FR2634382B1 (en) * 1988-07-21 1990-10-26 Applic Techn Photoniques ARTIFICIAL PANCREAS
CA2050057A1 (en) * 1991-03-04 1992-09-05 Adam Heller Interferant eliminating biosensors
US5593852A (en) 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
AU7978094A (en) * 1993-10-18 1995-05-08 Washington Research Foundation Device and method for monitoring and normalizing physiological parameters
EP0650738B1 (en) * 1993-10-28 2003-05-02 Medrad, Inc. Multi-patient fluid dispensing
DE1258262T1 (en) * 1993-10-28 2003-04-10 Medrad Inc Contrast delivery system
US5791344A (en) * 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5497772A (en) * 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
EP0692766B1 (en) * 1994-07-12 2002-05-08 Medrad, Inc. Closed loop information path for medical fluid delivery systems
US6397098B1 (en) * 1994-09-21 2002-05-28 Medrad, Inc. Data communication and control for medical imaging systems
US5840026A (en) * 1994-09-21 1998-11-24 Medrad, Inc. Patient specific dosing contrast delivery systems and methods
DE19502662C1 (en) * 1995-01-20 1996-11-21 Medac Klinische Spezialpraep Continuous infusion instrument into urinary bladder
US5665215A (en) * 1995-09-25 1997-09-09 Bayer Corporation Method and apparatus for making predetermined events with a biosensor
US6558900B2 (en) * 1996-07-12 2003-05-06 Emory University Regulation of apoptosis and in vitro model for studies thereof
JP3394262B2 (en) 1997-02-06 2003-04-07 セラセンス、インク. Small volume in vitro analyte sensor
US5919216A (en) * 1997-06-16 1999-07-06 Medtronic, Inc. System and method for enhancement of glucose production by stimulation of pancreatic beta cells
DE19756872B4 (en) 1997-12-19 2005-06-02 Siemens Ag Device for administering an infusion and / or perfusion to a patient
US6103033A (en) * 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6134461A (en) * 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6368272B1 (en) 1998-04-10 2002-04-09 Proactive Metabolics Company Equipment and method for contemporaneous decision supporting metabolic control
US6835175B1 (en) 1998-04-10 2004-12-28 Proactive Metabolics Co. Medical devices for contemporaneous decision support in metabolic control
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US7037277B1 (en) 1998-07-21 2006-05-02 Spectrx, Inc. System and method for fluid management in a continuous fluid collection and sensor device
US7384396B2 (en) 1998-07-21 2008-06-10 Spectrx Inc. System and method for continuous analyte monitoring
US6113574A (en) * 1998-07-27 2000-09-05 Spinello; Ronald P. Anesthetic injection apparatus and methods
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6251260B1 (en) 1998-08-24 2001-06-26 Therasense, Inc. Potentiometric sensors for analytic determination
US6591125B1 (en) * 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6188648B1 (en) 1998-11-03 2001-02-13 Toni L. Olsen Diabetic care overview wristwatch
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
US6654625B1 (en) 1999-06-18 2003-11-25 Therasense, Inc. Mass transport limited in vivo analyte sensor
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
US6485461B1 (en) 2000-04-04 2002-11-26 Insulet, Inc. Disposable infusion device
US6599281B1 (en) 2000-05-03 2003-07-29 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
US6650951B1 (en) 2000-06-19 2003-11-18 International Business Machines Corporation Method and insulin pump for providing a forgotten bolus warning
US6669669B2 (en) * 2001-10-12 2003-12-30 Insulet Corporation Laminated patient infusion device
CA2771723C (en) * 2000-09-08 2016-03-29 Insulet Corporation Devices, systems and methods for patient infusion
DE60126325T2 (en) 2000-11-09 2007-11-08 Insulet Corp., Beverly DEVICE FOR THE TRANSCUTANEOUS DISPOSAL OF MEDICAMENTS
ATE311811T1 (en) 2000-12-21 2005-12-15 Insulet Corp REMOTE CONTROL MEDICAL DEVICE
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
CN1556716A (en) 2001-02-22 2004-12-22 ���Ͽع����޹�˾ Modular infusion device and method
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
AUPR632301A0 (en) * 2001-07-11 2001-08-02 Chee, Frederick Howe-Hui Infusion apparatus for regulating blood glucose levels
US6827702B2 (en) * 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
US8152789B2 (en) * 2001-10-23 2012-04-10 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US6989891B2 (en) * 2001-11-08 2006-01-24 Optiscan Biomedical Corporation Device and method for in vitro determination of analyte concentrations within body fluids
US20040078028A1 (en) * 2001-11-09 2004-04-22 Flaherty J. Christopher Plunger assembly for patient infusion device
US8504179B2 (en) 2002-02-28 2013-08-06 Smiths Medical Asd, Inc. Programmable medical infusion pump
US6692457B2 (en) 2002-03-01 2004-02-17 Insulet Corporation Flow condition sensor assembly for patient infusion device
US6830558B2 (en) 2002-03-01 2004-12-14 Insulet Corporation Flow condition sensor assembly for patient infusion device
US7109974B2 (en) * 2002-03-05 2006-09-19 Matsushita Electric Industrial Co., Ltd. Remote control system including an on-screen display (OSD)
US20050238507A1 (en) * 2002-04-23 2005-10-27 Insulet Corporation Fluid delivery device
US6960192B1 (en) 2002-04-23 2005-11-01 Insulet Corporation Transcutaneous fluid delivery system
US20040153032A1 (en) * 2002-04-23 2004-08-05 Garribotto John T. Dispenser for patient infusion device
US6656159B2 (en) 2002-04-23 2003-12-02 Insulet Corporation Dispenser for patient infusion device
US6656158B2 (en) 2002-04-23 2003-12-02 Insulet Corporation Dispenser for patient infusion device
JP3854190B2 (en) * 2002-04-26 2006-12-06 株式会社ジェイテクト Motor control device
US6723072B2 (en) 2002-06-06 2004-04-20 Insulet Corporation Plunger assembly for patient infusion device
EP1382363A1 (en) * 2002-07-15 2004-01-21 Novo Nordisk A/S Closed loop system for controlling blood glucose levels
US7018360B2 (en) 2002-07-16 2006-03-28 Insulet Corporation Flow restriction system and method for patient infusion device
US7144384B2 (en) * 2002-09-30 2006-12-05 Insulet Corporation Dispenser components and methods for patient infusion device
US7128727B2 (en) * 2002-09-30 2006-10-31 Flaherty J Christopher Components and methods for patient infusion device
AU2003287073B2 (en) * 2002-10-11 2009-01-08 Becton, Dickinson And Company System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
EP2284266B1 (en) * 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US20040116866A1 (en) * 2002-12-17 2004-06-17 William Gorman Skin attachment apparatus and method for patient infusion device
AU2003303597A1 (en) 2002-12-31 2004-07-29 Therasense, Inc. Continuous glucose monitoring system and methods of use
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
AU2004229538A1 (en) * 2003-04-15 2004-10-28 Optiscan Biomedical Corporation Dual measurement analyte detection system
US7271912B2 (en) * 2003-04-15 2007-09-18 Optiscan Biomedical Corporation Method of determining analyte concentration in a sample using infrared transmission data
EP1618389A1 (en) * 2003-04-15 2006-01-25 Optiscan Biomedical Corporation Sample element qualification
US20050182366A1 (en) * 2003-04-18 2005-08-18 Insulet Corporation Method For Visual Output Verification
US6968222B2 (en) 2003-05-02 2005-11-22 Oculir, Inc. Methods and device for non-invasive analyte measurement
US6958039B2 (en) * 2003-05-02 2005-10-25 Oculir, Inc. Method and instruments for non-invasive analyte measurement
US6975892B2 (en) * 2003-10-21 2005-12-13 Oculir, Inc. Methods for non-invasive analyte measurement from the conjunctiva
US8685053B2 (en) * 2003-05-22 2014-04-01 Boston Scientific Scimed, Inc. Tether equipped catheter
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US20050055243A1 (en) * 2003-06-30 2005-03-10 Dave Arndt Method and apparatus for managing data received from a medical device
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8626257B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US20080119703A1 (en) * 2006-10-04 2008-05-22 Mark Brister Analyte sensor
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US20050065760A1 (en) * 2003-09-23 2005-03-24 Robert Murtfeldt Method for advising patients concerning doses of insulin
US20050070847A1 (en) * 2003-09-29 2005-03-31 Van Erp Wilhelmus Petrus Martinus Maria Rapid-exchange balloon catheter with hypotube shaft
US9123077B2 (en) 2003-10-07 2015-09-01 Hospira, Inc. Medication management system
US8065161B2 (en) 2003-11-13 2011-11-22 Hospira, Inc. System for maintaining drug information and communicating with medication delivery devices
US20060224057A1 (en) * 2003-10-21 2006-10-05 Oculir, Inc. Methods for non-invasive analyte measurement
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
USD914881S1 (en) 2003-11-05 2021-03-30 Abbott Diabetes Care Inc. Analyte sensor electronic mount
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8364230B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8425417B2 (en) 2003-12-05 2013-04-23 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
US8364231B2 (en) * 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8425416B2 (en) 2006-10-04 2013-04-23 Dexcom, Inc. Analyte sensor
US7682351B2 (en) * 2003-12-17 2010-03-23 Aoki Thomas T Method for infusing insulin to a subject to improve impaired hepatic glucose processing
WO2009048462A1 (en) 2007-10-09 2009-04-16 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20060009727A1 (en) * 2004-04-08 2006-01-12 Chf Solutions Inc. Method and apparatus for an extracorporeal control of blood glucose
US20080009688A1 (en) * 2004-04-14 2008-01-10 Oculir, Inc. Methods for non-invasive analyte measurement
US20060258919A1 (en) * 2004-04-14 2006-11-16 Oculir, Inc. Non-Invasive Analyte Measurement Device for Measuring Tears and Other Ocular Elements Using Electromagnetic Radiation and Method of Using the Same
US20080051764A1 (en) * 2004-04-19 2008-02-28 Board Of Regents, The University Of Texas System Physiological Monitoring With Continuous Treatment
US8170803B2 (en) 2004-07-13 2012-05-01 Dexcom, Inc. Transcutaneous analyte sensor
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US7468033B2 (en) * 2004-09-08 2008-12-23 Medtronic Minimed, Inc. Blood contacting sensor
WO2006086019A2 (en) * 2004-10-21 2006-08-17 Optiscan Biomedical Corporation Methods of treating diabetes
EP1805499A4 (en) * 2004-10-21 2010-07-21 Optiscan Biomedical Corp Method and apparatus for determining an analyte concentration in a sample having interferent
CN101084036B (en) 2004-11-16 2011-10-26 梅德拉股份有限公司 System and method for determining transmission function of patients and performing model to response patients of drug infusions
HUE038724T2 (en) 2004-11-24 2018-11-28 Bayer Healthcare Llc Devices and systems for fluid delivery
US8571624B2 (en) 2004-12-29 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for mounting a data transmission device in a communication system
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US8545403B2 (en) 2005-12-28 2013-10-01 Abbott Diabetes Care Inc. Medical device insertion
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US8333714B2 (en) 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US20090105569A1 (en) 2006-04-28 2009-04-23 Abbott Diabetes Care, Inc. Introducer Assembly and Methods of Use
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US20060178633A1 (en) * 2005-02-03 2006-08-10 Insulet Corporation Chassis for fluid delivery device
US7785258B2 (en) * 2005-10-06 2010-08-31 Optiscan Biomedical Corporation System and method for determining a treatment dose for a patient
US8425444B2 (en) * 2006-04-11 2013-04-23 Optiscan Biomedical Corporation Anti-clotting apparatus and methods for fluid handling system
US7860542B2 (en) * 2005-02-14 2010-12-28 Optiscan Biomedical Corporation Analyte detection system with reduced sample volume
US20060189926A1 (en) * 2005-02-14 2006-08-24 Hall W D Apparatus and methods for analyzing body fluid samples
US20060200070A1 (en) * 2005-02-14 2006-09-07 Callicoat David N Method and apparatus for calibrating an analyte detection system with a calibration sample
US8251907B2 (en) 2005-02-14 2012-08-28 Optiscan Biomedical Corporation System and method for determining a treatment dose for a patient
US8936755B2 (en) 2005-03-02 2015-01-20 Optiscan Biomedical Corporation Bodily fluid composition analyzer with disposable cassette
US7364562B2 (en) * 2005-10-06 2008-04-29 Optiscan Biomedical Corp. Anti-clotting apparatus and methods for fluid handling system
US20060194325A1 (en) * 2005-02-14 2006-08-31 Gable Jennifer H Fluid handling cassette with a fluid control interface
US20090054754A1 (en) * 2007-08-21 2009-02-26 Mcmahon Dave Clinician-controlled semi-automated medication management
US20100168535A1 (en) * 2006-04-12 2010-07-01 Mark Ries Robinson Methods and apparatuses related to blood analyte measurement system
US20090156975A1 (en) * 2007-11-30 2009-06-18 Mark Ries Robinson Robust System and Methods for Blood Access
US8323194B2 (en) * 2009-12-18 2012-12-04 Inlight Solutions, Inc. Detection of bubbles during hemodynamic monitoring when performing automated measurement of blood constituents
US20090048576A1 (en) * 2007-08-13 2009-02-19 Mark Ries Robinson Managing Cross-contamination in Blood Samples Withdrawn from a Multilumen Catheter
US20090088615A1 (en) * 2007-10-01 2009-04-02 Mark Ries Robinson Indwelling Fiber Optic Probe for Blood Glucose Measurements
WO2007059476A2 (en) * 2005-11-15 2007-05-24 Luminous Medical, Inc. Blood analyte determinations
US20100094114A1 (en) * 2008-10-09 2010-04-15 Mark Ries Robinson Use of multiple calibration solutions with an analyte sensor with use in an automated blood access system
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US7552240B2 (en) * 2005-05-23 2009-06-23 International Business Machines Corporation Method for user space operations for direct I/O between an application instance and an I/O adapter
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US20080161723A1 (en) * 2006-09-06 2008-07-03 Optiscan Biomedical Corporation Infusion flow interruption method and apparatus
US9561001B2 (en) 2005-10-06 2017-02-07 Optiscan Biomedical Corporation Fluid handling cassette system for body fluid analyzer
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US20070179436A1 (en) * 2005-12-21 2007-08-02 Braig James R Analyte detection system with periodic sample draw and laboratory-grade analyzer
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US7981034B2 (en) * 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
EP2011438B1 (en) 2006-04-26 2013-06-12 Nikkiso Co., Ltd. Biological component measuring equipment and method of calibration of biological component measuring equipment
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US9119582B2 (en) 2006-06-30 2015-09-01 Abbott Diabetes Care, Inc. Integrated analyte sensor and infusion device and methods therefor
US8206296B2 (en) 2006-08-07 2012-06-26 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
GB0616566D0 (en) * 2006-08-19 2006-09-27 Rolls Royce Plc An alloy and method of treating titanium aluminide
US8478377B2 (en) 2006-10-04 2013-07-02 Dexcom, Inc. Analyte sensor
US8275438B2 (en) 2006-10-04 2012-09-25 Dexcom, Inc. Analyte sensor
US8562528B2 (en) 2006-10-04 2013-10-22 Dexcom, Inc. Analyte sensor
US8298142B2 (en) 2006-10-04 2012-10-30 Dexcom, Inc. Analyte sensor
US8447376B2 (en) 2006-10-04 2013-05-21 Dexcom, Inc. Analyte sensor
US8449464B2 (en) 2006-10-04 2013-05-28 Dexcom, Inc. Analyte sensor
AU2007317669A1 (en) 2006-10-16 2008-05-15 Hospira, Inc. System and method for comparing and utilizing activity information and configuration information from mulitple device management systems
US20100030073A1 (en) * 2006-12-29 2010-02-04 Medrad, Inc. Modeling of pharmaceutical propagation
WO2008085421A2 (en) * 2006-12-29 2008-07-17 Medrad, Inc. Patient-based parameter generation systems for medical injection procedures
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7972296B2 (en) * 2007-10-10 2011-07-05 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US8417311B2 (en) * 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US8597190B2 (en) 2007-05-18 2013-12-03 Optiscan Biomedical Corporation Monitoring systems and methods with fast initialization
US8412293B2 (en) * 2007-07-16 2013-04-02 Optiscan Biomedical Corporation Systems and methods for determining physiological parameters using measured analyte values
WO2008144575A2 (en) * 2007-05-18 2008-11-27 Optiscan Biomedical Corporation Fluid injection and safety system
US20100145175A1 (en) * 2008-08-22 2010-06-10 Soldo Monnett H Systems and methods for verification of sample integrity
US20090160656A1 (en) * 2007-10-11 2009-06-25 Mahesh Seetharaman Analyte monitoring system alarms
WO2008150917A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
AU2008262018A1 (en) 2007-06-08 2008-12-18 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
EP2562664B1 (en) * 2007-06-27 2020-11-25 Roche Diabetes Care GmbH System for determining an insulin delivery and communicating a dose in automated pancreas software
CN101821741B (en) 2007-06-27 2013-12-04 霍夫曼-拉罗奇有限公司 Medical diagnosis, therapy, and prognosis system for invoked events and method thereof
US8641618B2 (en) 2007-06-27 2014-02-04 Abbott Diabetes Care Inc. Method and structure for securing a monitoring device element
US8085151B2 (en) 2007-06-28 2011-12-27 Abbott Diabetes Care Inc. Signal converting cradle for medical condition monitoring and management system
EP2170165B1 (en) * 2007-07-17 2018-12-05 Bayer Healthcare LLC Systems for determination of parameters for a procedure, for estimation of cardiopulmonary function and for fluid delivery
WO2009048977A1 (en) * 2007-10-08 2009-04-16 Optiscan Biomedical Corporation Low draw volume analyte detection systems
CA2702113A1 (en) * 2007-10-11 2009-04-16 Optiscan Biomedical Corporation Synchronization and configuration of patient monitoring devices
EP2232250A1 (en) 2007-12-10 2010-09-29 Bayer HealthCare LLC Methods and systems for forming reagent with reduced background current
US8290559B2 (en) 2007-12-17 2012-10-16 Dexcom, Inc. Systems and methods for processing sensor data
US8517990B2 (en) 2007-12-18 2013-08-27 Hospira, Inc. User interface improvements for medical devices
US8608484B2 (en) * 2008-03-04 2013-12-17 Medrad, Inc. Dynamic anthropomorphic cardiovascular phantom
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US8315449B2 (en) 2008-06-24 2012-11-20 Medrad, Inc. Identification of regions of interest and extraction of time value curves in imaging procedures
US8175812B2 (en) * 2008-06-25 2012-05-08 Roche Diagnostics Operations, Inc. Method, system, and computer program product for calculating daily weighted averages of glucose measurements (or derived quantities) with time-based weights
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US9421330B2 (en) * 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
US10437962B2 (en) 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US20120011125A1 (en) 2008-12-23 2012-01-12 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US9918635B2 (en) 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US10456036B2 (en) * 2008-12-23 2019-10-29 Roche Diabetes Care, Inc. Structured tailoring
CN102265279B (en) 2008-12-23 2019-08-23 霍夫曼-拉罗奇有限公司 The Structural Testing Method and its equipment that diagnosis or treatment for chronic are supported
US8849458B2 (en) * 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US20100213057A1 (en) 2009-02-26 2010-08-26 Benjamin Feldman Self-Powered Analyte Sensor
US8271106B2 (en) 2009-04-17 2012-09-18 Hospira, Inc. System and method for configuring a rule set for medical event management and responses
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US8731639B2 (en) 2009-07-20 2014-05-20 Optiscan Biomedical Corporation Adjustable connector, improved fluid flow and reduced clotting risk
US9554742B2 (en) 2009-07-20 2017-01-31 Optiscan Biomedical Corporation Fluid analysis system
EP2456355B1 (en) 2009-07-20 2016-09-14 Optiscan Biomedical Corporation Adjustable connector and dead space reduction
US10475529B2 (en) 2011-07-19 2019-11-12 Optiscan Biomedical Corporation Method and apparatus for analyte measurements using calibration sets
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
WO2011026147A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
US8771251B2 (en) * 2009-12-17 2014-07-08 Hospira, Inc. Systems and methods for managing and delivering patient therapy through electronic drug delivery systems
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
JP5758409B2 (en) * 2010-03-05 2015-08-05 ベー.ブラウン メルズンゲン アーゲー System and method for monitoring a time period for a blood parameter monitoring process
EP2549918B2 (en) 2010-03-24 2023-01-25 Abbott Diabetes Care, Inc. Medical device inserters and processes of inserting and using medical devices
WO2011156522A1 (en) 2010-06-09 2011-12-15 Optiscan Biomedical Corporation Measuring analytes in a fluid sample drawn from a patient
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
CA2803169C (en) 2010-06-24 2020-09-22 Medrad, Inc. Modeling of pharmaceutical propagation and parameter generation for injection protocols
US11064921B2 (en) 2010-06-29 2021-07-20 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US20120173151A1 (en) 2010-12-29 2012-07-05 Roche Diagnostics Operations, Inc. Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
DK3575796T3 (en) 2011-04-15 2021-01-18 Dexcom Inc ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
EP2729784A4 (en) 2011-07-06 2015-05-13 Optiscan Biomedical Corp Sample cell for fluid analysis system
CA2844807C (en) 2011-08-19 2022-07-26 Hospira, Inc. Systems and methods for a graphical interface including a graphical representation of medical data
US9700672B2 (en) 2011-09-21 2017-07-11 Bayer Healthcare Llc Continuous multi-fluid pump device, drive and actuating system and method
AU2012325937B2 (en) 2011-10-21 2018-03-01 Icu Medical, Inc. Medical device update system
AU2012335830B2 (en) 2011-11-07 2017-05-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods
EP4056105B1 (en) 2011-12-11 2023-10-11 Abbott Diabetes Care, Inc. Analyte sensor devices
US10022498B2 (en) 2011-12-16 2018-07-17 Icu Medical, Inc. System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy
EP3549524B1 (en) 2012-03-30 2023-01-25 Insulet Corporation Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
JP6306566B2 (en) 2012-03-30 2018-04-04 アイシーユー・メディカル・インコーポレーテッド Air detection system and method for detecting air in an infusion system pump
HUE056182T2 (en) 2012-05-14 2022-01-28 Bayer Healthcare Llc Systems and methods for determination of pharmaceutical fluid injection protocols based on x-ray tube voltage
ES2743160T3 (en) 2012-07-31 2020-02-18 Icu Medical Inc Patient care system for critical medications
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US8834401B2 (en) * 2012-11-26 2014-09-16 Becton, Dickinson And Company Glucose management and dialysis method and apparatus
AU2014225658B2 (en) 2013-03-06 2018-05-31 Icu Medical, Inc. Medical device communication method
US9555379B2 (en) 2013-03-13 2017-01-31 Bayer Healthcare Llc Fluid path set with turbulent mixing chamber, backflow compensator
WO2014190264A1 (en) 2013-05-24 2014-11-27 Hospira, Inc. Multi-sensor infusion system for detecting air or an occlusion in the infusion system
ES2838450T3 (en) 2013-05-29 2021-07-02 Icu Medical Inc Infusion set that uses one or more sensors and additional information to make an air determination relative to the infusion set
AU2014274122A1 (en) 2013-05-29 2016-01-21 Icu Medical, Inc. Infusion system and method of use which prevents over-saturation of an analog-to-digital converter
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
EP3039596A4 (en) 2013-08-30 2017-04-12 Hospira, Inc. System and method of monitoring and managing a remote infusion regimen
US9662436B2 (en) 2013-09-20 2017-05-30 Icu Medical, Inc. Fail-safe drug infusion therapy system
US10311972B2 (en) 2013-11-11 2019-06-04 Icu Medical, Inc. Medical device system performance index
EP3071253B1 (en) 2013-11-19 2019-05-22 ICU Medical, Inc. Infusion pump automation system and method
US10569015B2 (en) 2013-12-02 2020-02-25 Bigfoot Biomedical, Inc. Infusion pump system and method
WO2015095239A1 (en) 2013-12-18 2015-06-25 Optiscan Biomedical Corporation Systems and methods for detecting leaks
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
JP6636442B2 (en) 2014-02-28 2020-01-29 アイシーユー・メディカル・インコーポレーテッド Infusion systems and methods utilizing dual wavelength optical in-pipe air detection
US9764082B2 (en) 2014-04-30 2017-09-19 Icu Medical, Inc. Patient care system with conditional alarm forwarding
AU2015266706B2 (en) 2014-05-29 2020-01-30 Icu Medical, Inc. Infusion system and pump with configurable closed loop delivery rate catch-up
US9724470B2 (en) 2014-06-16 2017-08-08 Icu Medical, Inc. System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy
US9539383B2 (en) 2014-09-15 2017-01-10 Hospira, Inc. System and method that matches delayed infusion auto-programs with manually entered infusion programs and analyzes differences therein
JP6989262B2 (en) 2014-10-27 2022-01-05 アセコー インコーポレイテッド Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US11344668B2 (en) 2014-12-19 2022-05-31 Icu Medical, Inc. Infusion system with concurrent TPN/insulin infusion
AU2016205275B2 (en) 2015-01-09 2020-11-12 Bayer Healthcare Llc Multiple fluid delivery system with multi-use disposable set and features thereof
WO2016134137A1 (en) 2015-02-18 2016-08-25 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
US10850024B2 (en) 2015-03-02 2020-12-01 Icu Medical, Inc. Infusion system, device, and method having advanced infusion features
US9878097B2 (en) 2015-04-29 2018-01-30 Bigfoot Biomedical, Inc. Operating an infusion pump system
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
CA2984939A1 (en) 2015-05-14 2016-11-17 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
CA2988094A1 (en) 2015-05-26 2016-12-01 Icu Medical, Inc. Infusion pump system and method with multiple drug library editor source capability
JP6858751B2 (en) 2015-08-20 2021-04-14 アセコー インコーポレイテッド Diabetes Management Therapy Advisor
US10716896B2 (en) 2015-11-24 2020-07-21 Insulet Corporation Wearable automated medication delivery system
WO2017091584A1 (en) 2015-11-25 2017-06-01 Insulet Corporation Wearable medication delivery device
US10449294B1 (en) 2016-01-05 2019-10-22 Bigfoot Biomedical, Inc. Operating an infusion pump system
US10987468B2 (en) 2016-01-05 2021-04-27 Bigfoot Biomedical, Inc. Operating multi-modal medicine delivery systems
WO2017123525A1 (en) 2016-01-13 2017-07-20 Bigfoot Biomedical, Inc. User interface for diabetes management system
CA3009351A1 (en) 2016-01-14 2017-07-20 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
WO2017152036A1 (en) 2016-03-03 2017-09-08 Bayer Healthcare Llc System and method for improved fluid delivery in multi-fluid injector systems
EP3454922B1 (en) 2016-05-13 2022-04-06 ICU Medical, Inc. Infusion pump system with common line auto flush
CA3027176A1 (en) 2016-06-10 2017-12-14 Icu Medical, Inc. Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion
NZ750032A (en) 2016-07-14 2020-05-29 Icu Medical Inc Multi-communication path selection and security system for a medical device
US10765807B2 (en) * 2016-09-23 2020-09-08 Insulet Corporation Fluid delivery device with sensor
CN110461217B (en) 2017-01-23 2022-09-16 雅培糖尿病护理公司 Systems, devices, and methods for analyte sensor insertion
US11045603B2 (en) 2017-02-22 2021-06-29 Insulet Corporation Needle insertion mechanisms for drug containers
EP3676854A1 (en) 2017-08-31 2020-07-08 Bayer Healthcare LLC Fluid path impedance assessment for improving fluid delivery performance
AU2018326379B2 (en) 2017-08-31 2024-03-21 Bayer Healthcare Llc Method for dynamic pressure control in a fluid injector system
US11786652B2 (en) 2017-08-31 2023-10-17 Bayer Healthcare Llc System and method for drive member position and fluid injector system mechanical calibration
US11478581B2 (en) 2017-08-31 2022-10-25 Bayer Healthcare Llc Fluid injector system volume compensation system and method
US11598664B2 (en) 2017-08-31 2023-03-07 Bayer Healthcare Llc Injector pressure calibration system and method
EP3687600B1 (en) 2017-09-26 2022-04-27 Insulet Corporation Needle mechanism module for drug delivery device
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
CN209606445U (en) 2017-10-24 2019-11-08 德克斯康公司 Pre-connection analyte sensor
US11147931B2 (en) 2017-11-17 2021-10-19 Insulet Corporation Drug delivery device with air and backflow elimination
US10089055B1 (en) 2017-12-27 2018-10-02 Icu Medical, Inc. Synchronized display of screen content on networked devices
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
CN112236826A (en) 2018-05-04 2021-01-15 英赛罗公司 Safety constraints for drug delivery systems based on control algorithms
ES2962660T3 (en) 2018-07-17 2024-03-20 Icu Medical Inc Systems and methods to facilitate clinical messaging in a network environment
EP3824386B1 (en) 2018-07-17 2024-02-21 ICU Medical, Inc. Updating infusion pump drug libraries and operational software in a networked environment
US11139058B2 (en) 2018-07-17 2021-10-05 Icu Medical, Inc. Reducing file transfer between cloud environment and infusion pumps
US10950339B2 (en) 2018-07-17 2021-03-16 Icu Medical, Inc. Converting pump messages in new pump protocol to standardized dataset messages
US10692595B2 (en) 2018-07-26 2020-06-23 Icu Medical, Inc. Drug library dynamic version management
WO2020023231A1 (en) 2018-07-26 2020-01-30 Icu Medical, Inc. Drug library management system
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
WO2020077223A1 (en) 2018-10-11 2020-04-16 Insulet Corporation Event detection for drug delivery system
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
US11278671B2 (en) 2019-12-04 2022-03-22 Icu Medical, Inc. Infusion pump with safety sequence keypad
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
WO2022020184A1 (en) 2020-07-21 2022-01-27 Icu Medical, Inc. Fluid transfer devices and methods of use
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US11135360B1 (en) 2020-12-07 2021-10-05 Icu Medical, Inc. Concurrent infusion with common line auto flush
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3837339A (en) * 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US3908657A (en) * 1973-01-15 1975-09-30 Univ Johns Hopkins System for continuous withdrawal of blood
US4003379A (en) * 1974-04-23 1977-01-18 Ellinwood Jr Everett H Apparatus and method for implanted self-powered medication dispensing
CA1040271A (en) * 1975-01-22 1978-10-10 Anthony M. Albisser Artificial beta cell
DE2513467C3 (en) * 1975-03-26 1979-10-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Device for infusing liquids into the human or animal body
US4055175A (en) * 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
US4073292A (en) * 1976-10-29 1978-02-14 William Edelman Control apparatus for the automatic treatment of diabetes

Also Published As

Publication number Publication date
SE7812146L (en) 1979-05-26
US4151845A (en) 1979-05-01
FR2409741B1 (en) 1982-08-27
IT7852043A0 (en) 1978-11-23
NL7811583A (en) 1979-05-29
JPS5717539B2 (en) 1982-04-12
DE2849367B2 (en) 1980-09-18
JPS5482885A (en) 1979-07-02
IT1106148B (en) 1985-11-11
FR2409741A1 (en) 1979-06-22
GB2009460A (en) 1979-06-13
DE2849367A1 (en) 1979-05-31
GB2009460B (en) 1982-04-28

Similar Documents

Publication Publication Date Title
CA1121243A (en) Blood glucose control apparatus
US4245634A (en) Artificial beta cell
CA1040271A (en) Artificial beta cell
US4055175A (en) Blood glucose control apparatus
US4464170A (en) Blood glucose control apparatus and method
Albisser et al. Clinical control of diabetes by the artificial pancreas
US20210038134A1 (en) Model predictive method and system for controlling and supervising insulin infusion
Shichiri et al. Glycaemic control in pancreatectomized dogs with a wearable artificial endocrine pancreas
US8348886B2 (en) Apparatus and method for controlling insulin infusion with state variable feedback
US4526568A (en) Diagnostic method and apparatus for clamping blood glucose concentration
US7267665B2 (en) Closed loop system for controlling insulin infusion
AU2022201374A1 (en) Closed loop control of physiological glucose
Weil et al. The red cell mass-arterial oxygen relationship in normal man: application to patients with chronic obstructive airway disease
US20170325736A1 (en) Closed-loop glucose and/or insulin control system
US20080188796A1 (en) Closed-Loop Method for Controlling Insulin Infusion
US20060052679A1 (en) Method and device for continuous monitoring of the concentration of an analyte
JP2001204817A (en) System for extrapolation of glucose concentration
US20230256167A1 (en) Initial total daily insulin setting for user onboarding
Freckmann et al. Recent advances in continuous glucose monitoring
GB1574267A (en) Apparatus for controlling a quantity of insulin infusion
CN115645679A (en) Self-adaptive closed-loop control method based on linear model
Sun et al. Impact of errors in carbohydrate estimation on control of blood glucose in type 1 diabetes
Pozhar et al. Control methods in automated glycemia maintaining system
CA1142231A (en) Artificial beta cell for controlling a quantity of insulin infusion
WO2022040947A1 (en) Closed-loop artificial pancreas insulin infusion control system

Legal Events

Date Code Title Description
MKEX Expiry
MKEX Expiry

Effective date: 19990406